ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Financial Results on March 12, 2013

Tue Mar 5, 2013 9:00am EST

* Reuters is not responsible for the content in this press release.

ACADIA to Host Conference Call and Webcast on Tuesday, March 12, 2013, at 5:00
p.m. Eastern Time

SAN DIEGO--(Business Wire)--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused
on innovative treatments that address unmet medical needs in neurological and
related central nervous system disorders, today announced that it will report
its financial results for the fourth quarter and year ended December 31, 2012 on
Tuesday, March 12, 2013, after the U.S. financial markets close. ACADIA's
management will host a conference call and webcast on Tuesday, March 12, 2013,
at 5:00 p.m. Eastern Time to discuss ACADIA`s financial results and development

The conference call may be accessed by dialing 866-510-0712 for participants in
the U.S. or Canada and 617-597-5380 for international callers (reference
passcode 78191729). A telephone replay of the conference call may be accessed
through March 26, 2013 by dialing 888-286-8010 for callers in the U.S. or Canada
and 617-801-6888 for international callers (reference passcode 59394169). The
conference call also will be webcast live on ACADIA`s website,, under the investors section and will be archived there
until March 26, 2013. 

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on innovative treatments that
address unmet medical needs in neurological and related central nervous system
disorders. ACADIA has a pipeline of product candidates led by pimavanserin,
which is in Phase III development as a potential first-in-class treatment for
Parkinson's disease psychosis. ACADIA also has clinical-stage programs for
chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced
preclinical programs directed at Parkinson`s disease and other neurological
disorders. All product candidates are small molecules that emanate from
discoveries made at ACADIA. ACADIA maintains a website at
to which ACADIA regularly posts copies of its press releases as well as
additional information and through which interested parties can subscribe to
receive email alerts. 

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are
forward-looking statements. These statements include but are not limited to
statements related to the progress and timing of ACADIA`s drug discovery and
development programs, either alone or with a partner, including clinical trials,
and the benefits to be derived from ACADIA`s product candidates, in each case
including pimavanserin. These statements are only predictions based on current
information and expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected in any of
such statements due to various factors, including the risks and uncertainties
inherent in drug discovery, development and commercialization, and
collaborations with others, and the fact that past results of clinical trials
may not be indicative of future trial results. For a discussion of these and
other factors, please refer to ACADIA`s annual report on Form 10-K for the year
ended December 31, 2011 as well as ACADIA`s subsequent filings with the
Securities and Exchange Commission. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof. This caution is made under the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. All forward-looking statements are
qualified in their entirety by this cautionary statement and ACADIA undertakes
no obligation to revise or update this press release to reflect events or
circumstances after the date hereof, except as required by law.

ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Executive Vice President,
Chief Financial Officer and Chief Business Officer

Copyright Business Wire 2013

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.